Zenas Biopharma’s lead autoimmune drug has been tied to a 95% reduction in a type of brain lesions over 12 weeks in a phase 2 multiple sclerosis (MS) study.  | Zenas Biopharma’s lead autoimmune drug ...

"Multiple sclerosis: three trials to watch" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

Bionxt launched the final animal study needed to prepare for human testing of BNT23001, its under-the-tongue version of ...

BARCELONA, Spain — Annual dosing of rituximab for relapsing-remitting multiple sclerosis (RRMS) was noninferior to the typical dosing schedule of once every 6 months, which could offer a more ...

Zenas BioPharma (NASDAQ:ZBIO) shares surged 80% on Monday following the release of highly encouraging Phase 2 results from ...

BioNxt Solutions Inc. (CSE:BNXT) (OTCQB:BNXTF) (FSE:BXT), a bioscience company developing next-generation drug delivery technologies, has launched a 15-day dosing optimization study for its lead ...

The National Multiple Sclerosis Society (Society) announces Shaping Tomorrow Together, a groundbreaking effort to highlight ...

Doctors are looking to recruit more people for the trial, which they say could one day be given as a single one-off treatment ...

A well-established diabetes drug alleviated brain inflammation in a female mouse model of multiple sclerosis, suggesting the ...

A multiple sclerosis (MS) patient in the UK was the first to receive CAR T cell therapy, invented by UCL researchers, in a ...